Omalizumab reduces asthma exacerbations among responders at 28 weeks: the INNOVATE study

被引：0
|
作者：
Bousquet, J. [1 ]
Humbert, M. [2 ]
Rao, S. [3 ]
Pethe, A. [4 ]
Manga, V [3 ]
机构：
[1] Hop Arnaud de Villeneuve, Serv Pneumol, Montpellier, France
[2] Univ Paris 11, Hop Bicetre, Paris, France
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Healthcare, Hyderabad, Andhra Pradesh, India
来源：
ALLERGY | 2014年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
1445
引用
收藏
页码：519 / 519
页数：1
相关论文
共 50 条
  • [1] Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
    Szefler, Stanley
    Antonova, Jenya
    Trzaskoma, Benjamin
    Ortiz, Benjamin
    Paknis, Brandee
    Iqbal, Ahmar
    Goldstein, Stanley
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [2] Metabolomics to identify omalizumab responders among children with severe asthma: A prospective study
    Carraro, Silvia
    Di Palmo, Emanuela
    Licari, Amelia
    Barni, Simona
    Caldarelli, Valeria
    De Castro, Giovanna
    Di Marco, Antonio
    Fenu, Grazia
    Giordano, Giuseppe
    Lombardi, Enrico
    Pirillo, Paola
    Stocchero, Matteo
    Volpini, Alessandro
    Zanconato, Stefania
    Rusconi, Franca
    ALLERGY, 2022, 77 (09) : 2852 - 2856
  • [3] Omalizumab treatment reduces asthma exacerbations regardless of airway bronchodilator reversibility
    DeLeon, Samuel
    Barsanti, Franco
    Holweg, Cecile T. J.
    Yoo, Bongin
    Creasy, Blaine
    Wechsler, Michael E.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (08): : 2181 - +
  • [4] Omalizumab pre-season treatment reduces Fall asthma exacerbations
    Teach, Stephen J.
    JOURNAL OF PEDIATRICS, 2016, 172 : 225 - 226
  • [5] Omalizumab add-on therapy reduces exacerbations among responders: A pooled NNT analysis from 5 phase 3 studies
    Kasujee, Ismail
    Bader, Giovanni
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [6] Metabolomic approach in the characterization of omalizumab responders and non-responders among children with severe asthma: a multicenter prospective study
    Carraro, Silvia
    Di Palmo, Emanuela
    Barni, Simona
    Caldarelli, Valeria
    De Castro, Giovanna
    Di Marco, Antonio
    Fenu, Grazia
    Giordano, Giuseppe
    Licari, Amelia
    Lombardi, Enrico
    Pirillo, Paola
    Stocchero, Matteo
    Volpini, Alessandro
    Zanconato, Stefania
    Rusconi, Franca
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [7] Exploring the effect on asthma control of omalizumab reduction after 28 weeks treatment
    Slavin, R.
    Lowe, P.
    Feriol, C.
    Fox, H.
    Carpenter, L.
    Martin, C.
    Sallas, W.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : S308 - S308
  • [8] Review: Omalizumab added to corticosteroids reduces exacerbations and corticosteroid use in adults and children with asthma
    Thien, Francis
    ANNALS OF INTERNAL MEDICINE, 2011, 154 (10)
  • [9] Omalizumab reduces exacerbations and healthcare utilisation in severe allergic asthma patients UK clinical practice - APEX II study
    Menzies-Gow, Andrew
    Masoli, Matthew
    Heaney, Liam
    Corrigan, Christopher
    De Lorio, Fosca
    Niven, Rob
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [10] Omalizumab therapy reduces asthma exacerbations and is rated as effective by physicians in children with severe allergic (IgE-mediated) asthma
    Kulus, M.
    Hebert, J.
    Garcia, E.
    Taylor, A. F.
    Vidaurre, C. F.
    Blogg, M.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2009, 39 (12): : 1952 - 1952
12345